MX2019008808A - Compuesto de pirimidina y su uso farmaceutico. - Google Patents

Compuesto de pirimidina y su uso farmaceutico.

Info

Publication number
MX2019008808A
MX2019008808A MX2019008808A MX2019008808A MX2019008808A MX 2019008808 A MX2019008808 A MX 2019008808A MX 2019008808 A MX2019008808 A MX 2019008808A MX 2019008808 A MX2019008808 A MX 2019008808A MX 2019008808 A MX2019008808 A MX 2019008808A
Authority
MX
Mexico
Prior art keywords
pharmaceutical use
pyrimidine compound
compound
pyrimidine
cancer
Prior art date
Application number
MX2019008808A
Other languages
English (en)
Inventor
Jong Kang Seok
Hwan Bae In
Gil Ahn Young
Hyun Suh Kwee
Jin Ham Young
Yul Choi Jae
Hee KIM Seo
Woo Kim Tae
Original Assignee
Hanmi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharma Co Ltd filed Critical Hanmi Pharma Co Ltd
Publication of MX2019008808A publication Critical patent/MX2019008808A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan un compuesto de pirimidina representado por la Fórmula 1, un método para prepararlo y un uso farmacéutico del compuesto de pirimidina para la prevención o el tratamiento del cáncer.
MX2019008808A 2017-01-26 2018-01-26 Compuesto de pirimidina y su uso farmaceutico. MX2019008808A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170012766 2017-01-26
PCT/KR2018/001193 WO2018139903A1 (ko) 2017-01-26 2018-01-26 피리미딘 화합물 및 그의 의약 용도

Publications (1)

Publication Number Publication Date
MX2019008808A true MX2019008808A (es) 2019-09-16

Family

ID=62979563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008808A MX2019008808A (es) 2017-01-26 2018-01-26 Compuesto de pirimidina y su uso farmaceutico.

Country Status (23)

Country Link
US (2) US10280154B2 (es)
EP (2) EP3514153B1 (es)
JP (3) JP6608565B2 (es)
KR (1) KR101954369B1 (es)
CN (1) CN110214138A (es)
AR (1) AR110778A1 (es)
AU (1) AU2018211880B2 (es)
BR (1) BR112019015256A2 (es)
CA (1) CA3050239A1 (es)
DK (1) DK3514153T3 (es)
EA (1) EA039868B1 (es)
ES (1) ES2890668T3 (es)
HU (1) HUE056472T2 (es)
IL (2) IL290745B2 (es)
MX (1) MX2019008808A (es)
PH (1) PH12019501690A1 (es)
PL (1) PL3514153T3 (es)
PT (1) PT3514153T (es)
SA (1) SA519402288B1 (es)
SG (1) SG11201906435SA (es)
TW (1) TWI810172B (es)
WO (1) WO2018139903A1 (es)
ZA (1) ZA201905020B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR110778A1 (es) * 2017-01-26 2019-05-02 Hanmi Pharm Ind Co Ltd Compuestos de pirimidina y su uso farmacéutico
KR101954370B1 (ko) * 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
AU2019203034B1 (en) 2018-07-25 2019-09-26 Hanmi Pharm. Co., Ltd. Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
PE20212153A1 (es) 2019-02-22 2021-11-09 Hanmi Pharm Ind Co Ltd Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda
KR20200102949A (ko) * 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물
WO2020171649A1 (ko) * 2019-02-22 2020-08-27 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
CN111606889B (zh) * 2019-02-25 2023-03-07 上海翰森生物医药科技有限公司 4-(1-环丙基-1h-吲哚-3-基)-n-苯基嘧啶-2-胺衍生物的制备方法
MX2021015724A (es) 2019-06-27 2022-05-16 Hanmi Pharm Ind Co Ltd Composición farmacéutica para el tratamiento de la leucemia mieloide aguda, que contiene inhibidores de flt3 y agentes quimioterapéuticos.
AU2022206470A1 (en) * 2021-01-07 2023-07-27 Ontario Institute For Cancer Research (Oicr) Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof
WO2023082052A1 (zh) * 2021-11-09 2023-05-19 暨南大学 环状2-氨基嘧啶类化合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US20110183975A1 (en) * 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN101723936B (zh) * 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
US20100105655A1 (en) * 2008-10-29 2010-04-29 Astrazeneca Ab Novel compounds 515
US20110005173A1 (en) * 2009-07-08 2011-01-13 Kraft Foods Global Brands Llc Method and Apparatus to Create a Contoured Flow Wrap Package
WO2011008915A1 (en) * 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
UY33539A (es) * 2010-08-02 2012-02-29 Astrazeneca Ab Compuestos químicos alk
EA029488B1 (ru) 2011-07-27 2018-04-30 Астразенека Аб Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака
US9187453B2 (en) * 2012-03-28 2015-11-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2014155300A2 (en) * 2013-03-28 2014-10-02 Aurigene Discovery Technologies Limited Substitued pyrimidine amine derivatives as tak-1 inhibitors
PT3126352T (pt) * 2014-04-04 2018-12-27 Syros Pharmaceuticals Inc Inibidores da quinase dependente de ciclina 7 (cdk7)
CN113121575A (zh) * 2014-08-25 2021-07-16 四川海思科制药有限公司 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途
CA3049175A1 (en) * 2017-01-17 2018-07-26 Astrazeneca Ab Jak1 selective inhibitors
AR110778A1 (es) * 2017-01-26 2019-05-02 Hanmi Pharm Ind Co Ltd Compuestos de pirimidina y su uso farmacéutico

Also Published As

Publication number Publication date
AU2018211880B2 (en) 2019-04-11
US10280154B2 (en) 2019-05-07
IL268010B (en) 2022-04-01
JP2019531315A (ja) 2019-10-31
HUE056472T2 (hu) 2022-02-28
IL290745B2 (en) 2023-11-01
IL290745B1 (en) 2023-07-01
SG11201906435SA (en) 2019-08-27
EP3514153A4 (en) 2020-04-29
PT3514153T (pt) 2021-09-22
TWI810172B (zh) 2023-08-01
ES2890668T3 (es) 2022-01-21
US20190127353A1 (en) 2019-05-02
PL3514153T3 (pl) 2022-01-17
EA039868B1 (ru) 2022-03-22
EP3514153A1 (en) 2019-07-24
AR110778A1 (es) 2019-05-02
JP6608565B2 (ja) 2019-11-20
JP2023027203A (ja) 2023-03-01
JP7191799B2 (ja) 2022-12-19
US20190031643A1 (en) 2019-01-31
BR112019015256A2 (pt) 2020-04-14
PH12019501690A1 (en) 2020-03-09
WO2018139903A1 (ko) 2018-08-02
CA3050239A1 (en) 2018-08-02
EP3514153B1 (en) 2021-07-07
KR101954369B1 (ko) 2019-03-05
IL268010A (en) 2019-09-26
IL290745A (en) 2022-04-01
TW201829396A (zh) 2018-08-16
DK3514153T3 (da) 2021-09-27
AU2018211880A1 (en) 2018-09-13
SA519402288B1 (ar) 2022-03-09
EA201991580A1 (ru) 2020-02-03
KR20180088317A (ko) 2018-08-03
EP3789386A1 (en) 2021-03-10
JP2020023554A (ja) 2020-02-13
ZA201905020B (en) 2020-12-23
US10519141B2 (en) 2019-12-31
CN110214138A (zh) 2019-09-06

Similar Documents

Publication Publication Date Title
PH12019501690A1 (en) Pyrimidine compound and pharmaceutical use thereof
ZA201906832B (en) Novel psma-binding agents and uses thereof
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
UA117976C2 (uk) Сполуки амінопіримідинілу як інгібітори jak
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
GEP20186933B (en) Substituted dihydroisoquinoline compounds
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
PH12019500196A1 (en) Compounds and compositions and uses thereof
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
PH12019501955A1 (en) Tri-cycle compound and applications thereof
MX2020005659A (es) Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia.
TN2019000211A1 (en) Antitumoral compounds
PH12017501130A1 (en) Indenyl compounds, pharmaceutical compositions, and medical uses thereof
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
PH12019500198A1 (en) Compounds and compositions and uses thereof
SA520411726B1 (ar) مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
UA117524C2 (uk) Стимулятори рослин, їх застосування та спосіб стимуляції рослин
SG11201803867TA (en) Sodium channel blocker
MY180727A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzeimer?s disease
MX2019000542A (es) Derivados de pirazolilaminobenzimidazol como inhibidores de jak.
PH12017501560A1 (en) Tetrahydropyranyl benzamide derivatives
MX2018015269A (es) Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos.